ARA-290 / Cibinetide

ARA 290 (cibinetide) is a synthetic peptide derived from erythropoietin's helix B region used in neuropathy and exploratory ophthalmic/metabolic research; the catalogue entry denotes the research grade peptide compound.

ARA-290 / Cibinetide is associated with neuroscience and translational research as an investigational, non erythropoietic 11 amino acid peptide derived from erythropoietin. Small early phase human studies have explored sarcoidosis associated small fiber neuropathy, diabetic macular oedema, metabolic endpoints and neurocognitive effects. Samples were small and findings preliminary; no authorised indication or regulator label has been identified, and the research does not establish clinical efficacy for a catalogue material.

ARA-290 / Cibinetide: Batch documents are not yet linked on this site. For this synthetic erythropoietin derived peptide the required evidence includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and purity specification; peptide content, counterion and residual solvent/water details; and any potency or bioassay used for release. No batch documentation is shown as available until the record for that specific item is linked and reviewed.

ARA-290 / Cibinetide: Storage depends on the documented supplied presentation; for this synthetic erythropoietin derived peptide confirm dry/lyophilised versus solution form, counterion and concentration, solvent or buffer composition, pH sensitivity, container closure compatibility and freeze/thaw behaviour as these determine chemical and physical stability. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.